Table 6.
Top canonical pathways of 3, 4, and 10 weeks on diet and tumor sample groups
| qPCR dataset | Ingenuity canonical pathways | B-H-adjusted P -value | Ratio | Molecules |
|---|---|---|---|---|
|
3 weeks |
Communication between Innate and Adaptive Immune Cells |
9.11E-03 |
2/109 |
CCL3L1/CCL3L3, IL4 |
| Granulocyte Adhesion and Diapedesisa |
9.33E-03a |
2/175a |
CCL3L1/CCL3L3, CCL24 |
|
| Agranulocyte Adhesion and Diapedesisa |
9.33E-03a |
2/186a |
CCL3L1/CCL3L3, CCL24 |
|
|
4 weeks |
Human Embryonic Stem Cell Pluripotency |
1.44E-04 |
3/156 |
BDNF, FZD5, LEFTY2 |
| Mouse Embryonic Stem Cell Pluripotency |
4.07E-03 |
2/99 |
LIF, FZD5 |
|
| Role of NANOG in Mammalian Embryonic Stem Cell Pluripotencya |
4.07E-03a |
2/114a |
LIF, FZD5 |
|
| Role of Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid Arthritis |
1.20E-02 |
2/238 |
TNFSF11, FZD5 |
|
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritisa |
1.83E-02a |
2/332a |
TNFSF11, FZD5 |
|
|
10 weeks |
Granulocyte Adhesion and Diapedesisa |
5.66E-09a |
8/166a |
IL1A, CXCR2, CCL17, CCL20, IL1B, CCL22, CCL19, CCL1 |
| Agranulocyte Adhesion and Diapedesisa |
5.66E-09a |
8/176a |
IL1A, CXCR2, CCL17, CCL20, IL1B, CCL22, CCL19, CCL1 |
|
| Hepatic Fibrosis / Hepatic Stellate Cell Activation |
1.55E-06 |
6/140 |
VEGFA, IL1A, TGFB1, TGFA, IL1B, PGF |
|
| Altered T Cell and B Cell Signaling in Rheumatoid Arthritis |
3.24E-06 |
5/86 |
IL1A, IL2, TGFB1, LTA, IL1B |
|
| Role of Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid Arthritisa |
3.32E-06a |
7/311a |
VEGFA, IL1A, TGFB1, LTA, IL1B, IL7, PGF |
|
|
Tumor |
Molecular Mechanisms of Cancer |
7.10E-07 |
7/378 |
TP53, CCND2, APAF1, BMP7, BRCA1, CTNNB1, BMP10 |
| p53 Signaling |
7.10E-07 |
5/96 |
TP53, CCND2, APAF1, BRCA1, CTNNB1 |
|
| Basal Cell Carcinoma Signaling |
1.27E-05 |
4/73 |
TP53, BMP7, CTNNB1, BMP10 |
|
| GADD45 Signaling |
1.43E-05 |
3/22 |
TP53, CCND2, BRCA1 |
|
| Role of NANOG in Mammalian Embryonic Stem Cell Pluripotencya | 4.54E-05a | 4/114a | TP53, BMP7, CTNNB1, BMP10 |
aPathways that are common between groups, with 10 weeks on diet, and tumor groups having an increased number of pathway molecules from 3 and 4 weeks on diet. B-H, Benjamini-Hochberg.